PRIME Follow up - Quadri Meningo Vacinees

Launched by PUBLIC HEALTH ENGLAND · Jun 22, 2016

Keywords

ClinConnect Summary

The UK was the first country in the world to introduce the meningococcal serogroup C conjugate vaccine (MCC) into its routine immunisation schedule in 1999. This very effectively reduced the incidence of disease, which was highest in those younger than 1 year through its routine use in the infant immunisation schedule, and those aged around 15-17 years through a catch up campaign . Subsequently, the meningococcal vaccination schedule has undergone several revisions, including:

* 2006 - a reduction in the number of doses given to infants from the manufacturer advised three to the JCVI instr...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individual is willing and able to give written informed consent for participation.
• • Individual was originally enrolled in the randomised parallel group study of quadrivalent meningococcal vaccination.
• Exclusion Criteria:
• • Known bleeding diathesis (or any condition that may be associated with a prolonged bleeding time).
• • Any other significant condition or circumstance which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.